How much does Wegovy cost? With and without insurance

What Wegovy costs per month

The honest answer: anywhere from $0 to over $1,300 a month, and your insurance card — not the drug — decides which end you land on. Here’s the full range:

Figures are drafts pending verification — always confirm current pricing before budgeting around any of them.

Wegovy cost without insurance

If your plan won’t cover it, skip the pharmacy counter and go direct. NovoCare Pharmacy — Novo Nordisk’s own cash-pay channel — sells Wegovy for about $499 a month, shipped to your door, pen or pill, no insurance involved. That’s the number that matters for the uninsured and the excluded; the ~$1,349 list price is what retail looks like with no program at all, and almost nobody should be paying it.

Two things the cash route doesn’t change: you still need a prescription, and there’s no generic semaglutide to trade down to — $499 is currently the floor for the real thing bought directly (telehealth providers bundle it with membership pricing that can land nearby).

Do the annual math before you commit, because this isn’t a 30-day purchase. At NovoCare’s rate, a year of Wegovy runs about $6,000 out of pocket — and the STEP 1 extension data says stopping usually means regaining most of the weight, so the realistic budget question is “can I sustain this?”, not “can I afford one month?”

Wegovy cost with insurance

This is where it gets messy, because weight-loss coverage in America is a patchwork. Some commercial plans cover Wegovy with a prior authorization; many employer plans carve out weight-loss drugs entirely, no matter what your doctor writes. Same drug, same diagnosis, $25 for your coworker and $1,349 for you — the plan document is the whole ballgame.

When a plan does cover it, expect a prior authorization: your prescriber documents that you meet the label’s criteria — a BMI of 30+, or 27+ with a weight-related condition — and some plans add step-therapy requirements or proof of a lifestyle program on top (⚠ verify typical PA hurdles). It’s paperwork, not a lottery; denials are frequently overturned on appeal when the criteria genuinely fit, so a first “no” isn’t the final answer.

One wrinkle worth knowing: Wegovy carries a second FDA-approved indication — reducing cardiovascular risk in adults with heart disease and excess weight, earned by the SELECT trial. Some plans that exclude “weight-loss drugs” still cover drugs prescribed for cardiovascular risk reduction, so for patients who meet that indication, it can be a legitimate coverage pathway where a weight-management claim would be denied (⚠ verify framing). That’s a conversation for your prescriber, not a billing trick — the indication has to actually fit.

If you’re covered, stack the savings card on top: with commercial insurance that covers Wegovy, it can bring copays down to $0–25 a month.

Does Medicare cover Wegovy?

Historically, no — Medicare Part D was barred from covering drugs for weight loss, full stop. The cardiovascular indication cracked that open: once Wegovy was approved to reduce heart-attack and stroke risk, Part D plans could cover it for that use (⚠ verify mechanics). And starting in 2026, an expansion brings Wegovy to eligible Medicare patients for around $50 a month (⚠ verify eligibility details) — the biggest single change in who can afford this drug since launch.

The catch: “eligible” is doing real work in that sentence. Plans differ, criteria apply, and the weight-loss-only exclusion still exists. Check your specific plan before assuming either way.

How to pay less for Wegovy

• Read the savings card fine print. It requires commercial insurance — government plans like Medicare and Medicaid are excluded — and the $0–25 tier assumes your plan covers Wegovy. Monthly maximums and enrollment terms apply (⚠ verify current terms).
• NovoCare is the uninsured baseline. ~$499/month direct from Novo. If anyone quotes you more for cash-pay brand Wegovy, you’re overpaying.
• Don’t pick the pill to save money. Novo priced the daily pill in line with the weekly pen (⚠ verify parity), so the choice is about needles and routine, not dollars.
• A lower dose doesn’t mean a lower bill. Every pen strength is priced the same (⚠ verify flat pricing) — so a slower titration helps with side effects, not your budget.
• There is no generic. Semaglutide is still under patent. Compounded semaglutide exists in a legal grey zone since the FDA declared the shortage over — we cover that landscape informationally in the semaglutide guide, but it isn’t FDA-approved Wegovy.
• Use pre-tax dollars. FSA/HSA funds generally apply to prescription costs — a quiet 20–30% discount for many households.